What Should Women Ask Before Paying a Peptide Clinic?

You want skin that looks smooth and firm, and you do not want to pay for a treatment a pharmacy cannot legally supply. Before you pay, ask if the peptide is FDA-approved or compounded, which licensed pharmacy prepares it, and what risks and follow-up are included. Many popular anti-aging peptides, including BPC-157, CJC-1295 and ipamorelin, are not FDA-approved for any human use (healthcare law summary), and CJC-1295 and ipamorelin appear on the FDA Category 2 list for compounding (FDA Category 2 list).

Is this FDA-approved or compounded, and why does it matter?

FDA-approved means the agency reviewed the finished drug for safety and efficacy. Compounded means a licensed pharmacy mixes a prescription for one person. A direct clinic says this out loud. Compounded drugs are not FDA-approved, the FDA does not review them for safety or efficacy, and use carries known and unknown risks that vary by person (telehealth disclosure example).

Wellness peptides sold for anti-aging, including BPC-157, thymosin beta-4 and CJC-1295 with ipamorelin blends, are not FDA-approved for any human use (healthcare law summary). If a salesperson calls them approved or skips the compounded label, treat that as a red flag and keep your money.

Can a licensed pharmacy legally make this peptide for me?

Most personal prescriptions come from traditional compounding pharmacies. Those pharmacies work under Section 503A, a federal rule. Under that rule a bulk ingredient is eligible when it is in an FDA-approved drug, has a USP or NF monograph (a public quality standard), or appears in Category 1, the allowed list (compounding eligibility explainer).

Category 2 means the FDA found significant safety risks for compounding, and pharmacies may not compound with those ingredients under Category 1 policies. The Category 2 list includes CJC-1295, ipamorelin acetate, AOD-9604, Melanotan II, KPV and injectable GHK-Cu (FDA Category 2 list). After the September 2023 listing, licensed compounding pharmacies could no longer legally prepare BPC-157 (BPC-157 Category 2 explainer). The FDA has sent warning letters to pharmacies that compounded drugs with Category 2 substances (health law review). Larger outsourcing facilities face narrow rules too. They may use bulk ingredients only when the ingredient is on the 503B Bulks List or the finished product is on the Drug Shortages List (healthcare law summary). Ask for the pharmacy name, license and rule it uses. A vague answer means you walk away.

What risks and follow-up should they explain upfront?

For BPC-157 and ipamorelin acetate, the FDA cites risk of an immune reaction and peptide-related impurities, notes clumping risk for ipamorelin, and notes ipamorelin contains unnatural amino acids that make quality testing harder (FDA Category 2 list). For CJC-1295, the FDA says it found serious adverse events including increased heart rate and a systemic vasodilatory reaction, where blood vessels widen across the body, and says available clinical data are limited (FDA Category 2 list). BPC-157 also has no standardized dosing, contraindication list or interaction profile from clinical trials (BPC-157 Category 2 explainer).

A responsible clinic puts those risks in writing, tells you who reviews your health history, what follow-up visits and labs you receive, and what to do if your heart races or you feel faint. If you want an anti-aging plan with licensed review and clear follow-up, take the HOD quiz to see your options.